BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer.
Reporting to the Operations Lead for Europe & New Markets, the System Support Analyst is responsible for optimizing employee productivity by supporting desktop applications and services within the Infrastructure & Operations team. The role is the primary contact for day-to-day GTS support for on-site and remote users and must be comfortable supporting demanding profiles, including executives.
This is a hands-on technical role supporting regulated applications, including GxP and G&A systems. As part of the Operations Team, the position supports employees, contractors, and vendors in a Windows enterprise environment. The successful candidate must work effectively both independently and as a team member and will provide executive support and support on-site and remote meetings.
None.
Windows 11, Microsoft Office 365, AWS, SCCM, Microsoft Intune, MDM, Active Directory, Polycom, Microsoft Teams, Zoom, macOS, Android, and iOS.
Occasionally – less than 10%
Salary Range Switzerland: 98,600.00 CHF - 123,200.00 CHF
Global Competencies
When we exhibit our values of Patients First, Driving Excellence, Bold Ingenuity, and Collaborative Spirit, through our twelve global competencies below, we help get more affordable medicines to more patients around the world.
We are proud to be an equal opportunity employer. BeOne does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, disability, national origin, veteran status or any other basis covered by appropriate law. All employment is decided on the basis of qualifications, merit, and business need.

Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible.
To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.